Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famotidine for reduction of radiotherapy side effects in prostate cancer
IRCT20231121060132N1Phase 3Completed
- Sponsor
- Kermanshah University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of famotidine in prostate cancer (PCa) (2 arms), sponsored by Kermanshah University of Medical Sciences. Primary endpoints: mucosal damage, lymphocytopenia and 3 more. Started Nov 2023; status: completed.
02
Drugs
famotidine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on IRCT20231121060132N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231121060132N1.